Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Lymphoid 1Colorectal Neoplasms 1

Interventions

ibrutinib 3Vincristine 2Methotrexate 2tozasertib 1thymoglobulin 1romiplostim 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1lucatumumab 1fludarabine 1fenebrutinib 1enzastaurin 1duvelisib 1Receptors, Chimeric Antigen 1Prednisone 1Prednisolone 1Hydrocortisone 1Hu-Mik-beta-1 monoclonal antibody 1Doxorubicin 1Dasatinib 1Cytarabine 1Cyclophosphamide 1Busulfan 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphoid × tozasertib × Clear all
NCT00111683 2015-08-25

MK0457 in Patients With Leukemia (0457-003)

Merck Sharp & Dohme LLC

Phase 1 Completed
28 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡